Great Tree Pharmacy Co Ltd

Great Tree Pharmacy Co Ltd has a fully diluted share count of 149,699,000 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key financial ratios such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry medians. The company operates exclusively in Taiwan, with no disclosed segment or geographic diversification. All revenue is attributed to a single geographic market, which may expose the business to localized economic or regulatory risks. No growth trajectory is provided in the outlook, and no numeric deltas are available for the current or next fiscal year. Analysts have assigned a mean recommendation of 3.50, indicating a neutral stance, with three "hold" ratings and no "buy" or "strong buy" ratings. The company's risk assessment indicates low dilution potential, with no near-term dilution pressure identified. However, liquidity risk remains unassessed due to missing balance-sheet data. No recent filings or transcripts are provided to inform recent events or strategic developments. Analysts have provided a mean price target of 90.00 TWD, with a median of 90.00 TWD and a range from 85.00 to 95.00 TWD. The absence of strong buy or buy ratings suggests limited upside potential in the near term.